Pyrexar Medical brings Hyperthermia to South Korea

Salt Lake City, UT, April 16, 2015 (Newswire.com) - Pyrexar Medical, the makers of PYREXAR HT Hyperthermia-based cancer treatment systems, announced today that it has received orders for the first two units, of a multi-unit contract, for the BSD-2000 Deep Regional Hyperthermia Systems from the distribution group HanBeam Technology. Hyperthermia is a type of cancer treatment in which tumors are exposed to elevated body temperatures, between 104˚ and 113°F.  Research has shown that high temperatures can damage and kill cancer cells, usually with minimal injury to normal tissues.

Hyperthermia treatment has achieved high clinical response when combined with radiotherapy in the treatment of cancer. “We are very please to have HanBeam Technology as a distribution partner” says Mark Falkowski, CEO.  “HanBeam has a solid reputation as a radiation solutions provider in the Korean peninsula”.

We are very please to have HanBeam Technology as a distribution partner. HanBeam has a solid reputation as a radiation solutions provider in the Korean peninsula.

Mark Falkowski, CEO

ABOUT HANBEAM TECHNOLOGY:
HanBeam Technology Co., Ltd is known for installing the world’s first single-room proton therapy system and the world’s first View Ray system combining MRI, radiation cancer treatment, Intraoperative Radiation Therapy (IORT) and the BSD-2000 Hyperthermia system capable of thermal cancer treatment. The company is supplying and managing cutting-edge cancer treatment equipment to South Korea and beyond. Building on medical equipment expertise and experiences, the company has spearheaded the adoption of advanced medical equipment to the country.

For the past decade, the company contributed to the use of enhanced robotic radio surgery by providing Cyberknife to major Korean cancer treatment centers and university hospitals, improving patient care in the hospital environment.

ABOUT PYREXAR MEDICAL:
With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues.

Multi-center clinical trials in the US, Europe and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high risk soft tissue sarcoma, melanoma and other malignancies.

Pyrexar Medical is based in Salt Lake City, UT, USA. For more information please visit our web page at: www.pyrexar.com